Table 3.

Treatment-related adverse events in the total population (n = 117).

Adverse Event	Any Grade	Grade 3/4
Any AE	55 (47.0%)	8 (6.8%)
Hypothyroidism	9 (7.7%)	0
Fatigue	5 (4.3%)	0
Skin rash	5 (4.3%)	2 (1.7%)
Anemia	4 (3.4%)	1 (0.9%)
AST/ALT elevated	3 (2.6%)	1 (0.9%)
Nausea	3 (2.6%)	0
Abdominal pain	3 (2.6%)	0
Dyspnea	3 (2.6%)	0
Colitis	2 (1.7%)	1 (0.9%)
Neutropenia	2 (1.7%)	1 (0.9%)
Thrombocytopenia	2 (1.7%)	0
Hyperphosphatemia	2 (1.7%)	0
Hypoalbuminemia	2 (1.7%)	0
Renal insufficiency	2 (1.7%)	0
Cough	2 (1.7%)	0
Hyperthyroidism	1 (0.9%)	0
Pneumonitis with pulmonary edema	1 (0.9%)	1 (0.9%)
Constipation	1 (0.9%)	0
Vomiting	1 (0.9%)	0
Dizziness	1 (0.9%)	0
Guillain-Barré syndrome	1 (0.9%)	1 (0.9%)
Any AE leading to discontinuation
Guillain-Barre syndrome	1	1
Colitis	1	1
Pneumonitis with pulmonary edema	1	1

AE, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase.